WEKO3
インデックスリンク
アイテム
Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: A reliable marker for a benign subset of bone marrow failure
http://hdl.handle.net/2297/35212
http://hdl.handle.net/2297/35212739846bf-6105-44a3-b963-0efd441e81f3
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ME-PR-SEIKI-Y-901.pdf (1.1 MB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2017-10-03 | |||||
| タイトル | ||||||
| タイトル | Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: A reliable marker for a benign subset of bone marrow failure | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
Seiki-Shimizu, Yu
× Seiki-Shimizu, Yu× Sasaki, Yumi× Hosokawa, Kohei× Saito, Chizuru× Sugimori, Naomi× Yamazaki, Hirohito× Takami, Akiyoshi× Nakao , Shinji |
|||||
| 書誌情報 |
Haematologica 巻 98, 号 6, p. 901-907, 発行日 2013-01-01 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0390-6078 | |||||
| NCID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AA00660912 | |||||
| DOI | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.3324/haematol.2012.066217 | |||||
| 出版者 | ||||||
| 出版者 | Ferrata Storti Foundation | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Although myelodysplastic syndromes are heterogeneous disorders comprising a benign subset of bone marrow failure similar to aplastic anemia, no laboratory test has been established to distinguish it from bone marrow failures that can evolve into acute myeloid leukemia. Plasma thrombopoietin levels were measured in 120 patients who had myelodysplastic syndrome with thrombocytopenia (< 100 × 109/L) to determine any correlation to markers associated with immune pathophysiology and outcome. Thrombopoietin levels were consistently low for patients with refractory anemia with excess of blasts, while patients with other myelodysplatic syndrome subsets had more variable results. Patients with thrombopoietin levels of 320 pg/mL and over had increased glycosylphosphatidylinositol- anchored protein-deficient blood cells (49.1% vs. 0%), were more likely to have a low International Prognostic Scoring System (IPSS) score (≤1.0, 100% vs. 65.5%), a higher response rate to immunosuppressive therapy (84.2% vs. 14.3%), and a better 5-year progression-free survival rate (94.1% vs. 63.6% for refractory cytopenia with unilineage dysplasia; 100.0% vs. 44.4% for refractory cytopenia with multilineage dysplasia). In conclusion, increased plasma thrombopoietin levels were associated with a favorable prognosis of bone marrow failure and could, therefore, represent a reliable marker for a benign subset of myelodysplastic syndrome. © 2013 Ferrata Storti Foundation. | |||||
| 著者版フラグ | ||||||
| 出版タイプ | AM | |||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
